Show Nav →
Please include the following statement when referencing the CPTAC Assay Portal
We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.

Overview Data source: UniProt

Official Gene Symbol Other Aliases
CHEK2 CDS1, CHK2, RAD53
Sequence Length (AA) Molecular Weight (Da)
543 60915
Protein Name
Serine/threonine-protein kinase Chk2
Sources
UniProt
PhosphoSitePlus ®
GeneCards
Human Protein Atlas

Protein Sequence hover to view complete sequence

10 20 30 40 50
MSRESDVEAQ QSHGSSACSQ PHGSVTQSQG SSSQSQGISS SSTSTMPNSS
60 70 80 90 100
QSSHSSSGTL SSLETVSTQE LYSIPEDQEP EDQEPEEPTP APWARLWALQ
110 120 130 140 150
DGFANLECVN DNYWFGRDKS CEYCFDEPLL KRTDKYRTYS KKHFRIFREV
160 170 180 190 200
GPKNSYIAYI EDHSGNGTFV NTELVGKGKR RPLNNNSEIA LSLSRNKVFV
210 220 230 240 250
FFDLTVDDQS VYPKALRDEY IMSKTLGSGA CGEVKLAFER KTCKKVAIKI
260 270 280 290 300
ISKRKFAIGS AREADPALNV ETEIEILKKL NHPCIIKIKN FFDAEDYYIV
310 320 330 340 350
LELMEGGELF DKVVGNKRLK EATCKLYFYQ MLLAVQYLHE NGIIHRDLKP
360 370 380 390 400
ENVLLSSQEE DCLIKITDFG HSKILGETSL MRTLCGTPTY LAPEVLVSVG
410 420 430 440 450
TAGYNRAVDC WSLGVILFIC LSGYPPFSEH RTQVSLKDQI TSGKYNFIPE
460 470 480 490 500
VWAEVSEKAL DLVKKLLVVD PKARFTTEEA LRHPWLQDED MKRKFQDLLS
510 520 530 540 543
EENESTALPQ VLAQPSTSRK RPREGEAEGA ETTKRPAVCA AVL

Data source: UniProt


Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs

Uniprot Database Entry PhosphoSitePlus ®

Click a point on a node
to view detailed assay information below
All other points link out to UniProt



Phosphorylation Acetylation Ubiquitylation Other

loading

Loader

Assay Details for CPTAC-5892 Collapse assay details

Data source: Panorama

Official Gene Symbol
CHEK2
Peptide Modified Sequence
ILGETS[+79.966331]LM[+15.994915]R
Modification Type
Phospho (ST), Oxidation (M)
Protein - Site of Modification
380, 382
Peptide - Site of Modification
6, 8
Peptide Start
374
Peptide End
382
CPTAC ID
CPTAC-5892
Peptide Molecular Mass
1,114.5094
Species
Homo sapiens (Human)
Assay Type
Enrichment MRM
Enrichment Method
peptide immunoaffinity
Matrix
Cell Lysate
Submitting Laboratory
Fred Hutchinson Cancer Research Center
Submitting Lab PI
Amanda Paulovich

Publication

View Details (opens in a new window)

Targeted Mass Spectrometry Enables Quantification of Novel Pharmacodynamic Biomarkers of ATM Kinase Inhibition. Whiteaker JR, Wang T, Zhao L, Schoenherr RM, Kennedy JJ, Voytovich U, Ivey RG, Huang D, Lin C, Colantonio S, Caceres TW, Roberts RR, Knotts JG, Kaczmarczyk JA, Blonder J, Reading JJ, Richardson CW, Hewitt SM, Garcia-Buntley SS, Bocik W, Hiltke T, Rodriguez H, Harrington EA, Barrett JC, Lombardi B, Marco-Casanova P, Pierce AJ, Paulovich AG. Cancers (Basel). 2021 Jul 30;13(15):3843. doi: 10.3390/cancers13153843. PMID: 34359745


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
Sciex 5500 QTRAP
Internal Standard
peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus R
LC
Eksigent 425
Column Packing
Reprosil
Column Dimensions
75um x 15cm
Flow Rate
300 nL/min

Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

  Average intra-assay CV
(within day CV)
Average inter-assay CV
(between day CV)
Total CV
equation
n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
y4-98 (1+) 62.4 22.1 27.4 88.9 40.4 35.6 108.6 46 44.9 15 27 15
y4 (1+) 34.9 22.3 16.7 38.7 21.3 12 52.1 30.8 20.6 12 24 12
y5-98 (1+) 39.6 11.4 8 44.7 18.7 15.6 59.7 21.9 17.5 15 27 15
y5 (1+) 29.4 11.7 5.7 42.1 17.5 12.7 51.3 21.1 13.9 15 27 15
y6 (1+) 83.1 33 15.6 74.2 29.9 22.3 111.4 44.5 27.2 12 24 12
y7-98 (1+) 33.2 8 4.2 42.2 13.7 13.1 53.7 15.9 13.8 15 27 15
y7 (1+) 19.8 6.2 5 24.7 10.7 14.9 31.7 12.4 15.7 15 27 15
sum 16.5 4.8 3 23.3 12.5 14.5 28.6 13.4 14.8 15 27 15


Additional Resources and Comments


Assay Details for CPTAC-5893 Collapse assay details

Data source: Panorama

Official Gene Symbol
CHEK2
Peptide Modified Sequence
TLC[+57.021464]GTPTYLAPEVLVSVGTAGYNR
Modification Type
Carbamidomethyl Cysteine
Protein - Site of Modification
386
Peptide - Site of Modification
3
Peptide Start
383
Peptide End
406
CPTAC ID
CPTAC-5893
Peptide Molecular Mass
2,538.2788
Species
Homo sapiens (Human)
Assay Type
Enrichment MRM
Enrichment Method
peptide immunoaffinity
Matrix
Cell Lysate
Submitting Laboratory
Fred Hutchinson Cancer Research Center
Submitting Lab PI
Amanda Paulovich

Publication

View Details (opens in a new window)

Targeted Mass Spectrometry Enables Quantification of Novel Pharmacodynamic Biomarkers of ATM Kinase Inhibition. Whiteaker JR, Wang T, Zhao L, Schoenherr RM, Kennedy JJ, Voytovich U, Ivey RG, Huang D, Lin C, Colantonio S, Caceres TW, Roberts RR, Knotts JG, Kaczmarczyk JA, Blonder J, Reading JJ, Richardson CW, Hewitt SM, Garcia-Buntley SS, Bocik W, Hiltke T, Rodriguez H, Harrington EA, Barrett JC, Lombardi B, Marco-Casanova P, Pierce AJ, Paulovich AG. Cancers (Basel). 2021 Jul 30;13(15):3843. doi: 10.3390/cancers13153843. PMID: 34359745


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
Sciex 5500 QTRAP
Internal Standard
peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus R
LC
Eksigent 425
Column Packing
Reprosil
Column Dimensions
75um x 15cm
Flow Rate
300 nL/min

Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

  Average intra-assay CV
(within day CV)
Average inter-assay CV
(between day CV)
Total CV
equation
n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
b15 (2+) 47.1 22.4 13.1 69.1 33 27.1 83.6 39.9 30.1 16 26 15
b14 (2+) 48.8 22 11.3 77.5 43.7 25.3 91.6 48.9 27.7 16 26 15
b13 (2+) 46.9 21.3 12.4 64.7 43 32.4 79.9 48 34.7 16 26 15
y4 (1+) 42.5 10.9 9 74.5 32.5 23 85.8 34.3 24.7 16 26 15
y6 (1+) 65.4 13.9 6 64.4 43.5 19.6 91.8 45.7 20.5 16 26 15
y7 (1+) 43.5 13 8.6 71 36.4 25.6 83.3 38.7 27 16 26 15
y9 (1+) 41.2 17.6 13.6 72.6 53.8 39.7 83.5 56.6 42 16 26 15
sum 27.2 8 8.2 61.9 37.4 25.8 67.6 38.2 27.1 16 26 15


Additional Resources and Comments


Assay Details for CPTAC-5894 Collapse assay details

Data source: Panorama

Official Gene Symbol
CHEK2
Peptide Modified Sequence
TLC[+57.021464]GT[+79.966331]PTYLAPEVLVSVGTAGYNR
Modification Type
Carbamidomethyl Cysteine, Phospho (ST)
Protein - Site of Modification
386, 388
Peptide - Site of Modification
3, 5
Peptide Start
383
Peptide End
406
CPTAC ID
CPTAC-5894
Peptide Molecular Mass
2,618.2452
Species
Homo sapiens (Human)
Assay Type
Enrichment MRM
Enrichment Method
peptide immunoaffinity
Matrix
Cell Lysate
Submitting Laboratory
Fred Hutchinson Cancer Research Center
Submitting Lab PI
Amanda Paulovich

Publication

View Details (opens in a new window)

Targeted Mass Spectrometry Enables Quantification of Novel Pharmacodynamic Biomarkers of ATM Kinase Inhibition. Whiteaker JR, Wang T, Zhao L, Schoenherr RM, Kennedy JJ, Voytovich U, Ivey RG, Huang D, Lin C, Colantonio S, Caceres TW, Roberts RR, Knotts JG, Kaczmarczyk JA, Blonder J, Reading JJ, Richardson CW, Hewitt SM, Garcia-Buntley SS, Bocik W, Hiltke T, Rodriguez H, Harrington EA, Barrett JC, Lombardi B, Marco-Casanova P, Pierce AJ, Paulovich AG. Cancers (Basel). 2021 Jul 30;13(15):3843. doi: 10.3390/cancers13153843. PMID: 34359745


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
Sciex 5500 QTRAP
Internal Standard
peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus R
LC
Eksigent 425
Column Packing
Reprosil
Column Dimensions
75um x 15cm
Flow Rate
300 nL/min

Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

  Average intra-assay CV
(within day CV)
Average inter-assay CV
(between day CV)
Total CV
equation
n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
b17 (2+) 122.2 74.1 55.7 141 94 51.4 186.6 119.7 75.8 14 26 15
b15 (2+) 85.8 58.9 22.9 78.5 65.7 17 116.3 88.2 28.5 15 27 15
b14 (2+) 44.3 29 25.7 53.5 42.3 40.8 69.5 51.3 48.2 15 27 15
b13 (2+) 43.8 44.9 30.7 49.8 45.8 29.5 66.3 64.1 42.6 15 27 15
b6 (2+) 89.4 113.7 63.9 119 99.2 75.2 148.8 150.9 98.7 15 27 15
b9 (1+) 141.4 96.8 79.6 105.3 84.8 78.1 176.3 128.7 111.5 6 14 12
y9 (2+) 90.3 99.2 53 143.5 88.7 58.3 169.5 133.1 78.8 14 26 15
y15 (2+) 98.3 72.8 81.3 97.5 70.1 112 138.5 101.1 138.4 14 25 15
y4 (1+) 65.9 35.8 17.9 62.3 40.1 16.5 90.7 53.8 24.3 15 27 15
y6 (1+) 87.7 40.9 54.5 71.1 51.1 58.7 112.9 65.5 80.1 15 27 15
y7 (1+) 68.5 35.7 20 64.2 37.7 30.4 93.9 51.9 36.4 15 27 15
y9 (1+) 75.2 43.2 25.2 69.9 41.4 33 102.7 59.8 41.5 15 27 15
sum 23.7 15.3 9 25 24.8 12.3 34.4 29.1 15.2 15 27 15


Additional Resources and Comments